Varricchio Lilian, Mancini Annalisa, Migliaccio Anna Rita
Department of Medicine, Division of Hematology/Oncology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USA Tel.: +1 212 241 6974
Expert Rev Hematol. 2009 Jun 1;2(3):315-334. doi: 10.1586/ehm.09.17.
Primary myelofibrosis (PMF) belongs to the Philadelphia-negative myeloproliferative neoplasms and is a hematological disorder caused by abnormal function of the hematopoietic stem cells. The disease manifests itself with a plethora of alterations, including anemia, splenomegaly and extramedullary hematopoiesis. Its hallmarks are progressive marrow fibrosis and atypical megakaryocytic hyperplasia, two distinctive features used to clinically monitor disease progression. In an attempt to investigate the role of abnormal megakaryocytopoiesis in the pathogenesis of PMF, several transgenic mouse models have been generated. These models are based either on mutations that interfere with the extrinsic (thrombopoietin and its receptor, MPL) and intrinsic (the GATA1 transcription factor) control of normal megakaryocytopoiesis, or on known genetic lesions associated with the human disease. Here we provide an up-to-date review on the insights into the pathobiology of human PMF achieved by studying these animal models, with particular emphasis on results obtained with Gata1(low) mice.
原发性骨髓纤维化(PMF)属于费城染色体阴性的骨髓增殖性肿瘤,是一种由造血干细胞功能异常引起的血液系统疾病。该疾病表现为多种改变,包括贫血、脾肿大和髓外造血。其特征是进行性骨髓纤维化和非典型巨核细胞增生,这是用于临床监测疾病进展的两个显著特征。为了研究异常巨核细胞生成在PMF发病机制中的作用,已经建立了几种转基因小鼠模型。这些模型要么基于干扰正常巨核细胞生成的外在(血小板生成素及其受体MPL)和内在(GATA1转录因子)控制的突变,要么基于与人类疾病相关的已知基因损伤。在此,我们提供了一篇最新综述,介绍通过研究这些动物模型对人类PMF病理生物学的深入了解,特别强调了Gata1(low)小鼠的研究结果。